


## GABRIELA DE LARRAÑAGA PH.D.

### RESEARCH LINES

- **COVID-19:** biomarkers, genetics, clinical trials, MedTech.
- **Sepsis:** new approaches in prediction variables.
- **Pharmacogenetics** of Tuberculosis.
- Selection of genetic markers for venous **thromboembolic disease** in the argentine population. Construction of risk profiles with diagnostic utility.
- **Liver fibrosis:** impact of genetic variants related to thrombophilia on the progression of hepatic fibrosis.
- **Antiphospholipid antibodies** and obstetric complications.
- **Human immunodeficiency virus (HIV)** and coagulation disorders.
- Autoimmune diseases. Lupus-Rheumatoid Arthritis-Antiphospholipid Antibodies
- Inherited Thrombophilia and **Obstetric Complications.**

### SCIENTIFIC PUBLICATIONS





## PUBLICATION IN A NATIONAL SCIENTIFIC JOURNAL WITH PEER-REVIEWER

1. Sebastián Udry; Stephanie Morales Perez; Cristina Belizna, Federico Aranda; Enrique Esteve-Valverde; Silvia Perés Wingeyer; Diego Santiago Fernández Romero; José Omar Latino; **Gabriela de Larrañaga**; and Jaume Alijotas-Reig. An overall evaluation of the adjusted Global Antiphospholipid Syndrome Score in primary obstetric antiphospholipid syndrome patients. Is low-dose aspirin useful for primary thromboprophylaxis?. *Lupus* **2021**.
2. Moiana M, Aranda F, **G de Larrañaga**. A focus on the roles of histones in health and diseases. *Clinical Biochemistry*, **2021**,94:12-19  
<https://doi.org/10.1016/j.clinbiochem.2021.04.019>
3. Consenso argentino en gestión efectiva de clínicas de anticoagulación para. uso de dicumarínicos. José M Ceresetto, Cristina Duboscq, Jorge Korin, Carlos Fondevila, Patricia Casais, Andrea Rossi, Alejandra Scazziota, Marta Martinuzzo, María Ester Ariscancela, Claudio Rosas, Gonzalo Pombo, Carla Guimelli, Yolanda Adamczuk, Alejandra Martí, Diana Penschsky, Dardo Riveros, Dolores Puente, Lucía Celebrin, Soledad Molnar, Susana Meschengieser, Miguel Castro Ríos, Alicia Blanco16, Héctor Hendler, Andrés Brodsky, Analía Sanchez Luceros, Pedro Negri Aranguren, José Luis Fedele, Claudio Merlo, Pablo Raña, Carina Gumpel, Cecilia Colorio, Beatriz Grand, Virginia Canónico, Eleonora Rossi, Paulo Colimodio, Sergio Orlando, Daniel Fassi, Mirta Arias, Laura Viudez, Roberto Farreras, Pablo Martinez, Hugo Ferro, Claudia Casali, Alejandra Baques, Guillermo Arbesú, Susana Viñuales, Fernanda Medina, Verónica Cortes, María Del Carmen Gallo, Ludmila Ehelou, Luis Barrera, Irene Rey, **Gabriela Larrañaga**, Flavia Figueroa, Alicia Vilaseca, Isabel Kuri, Alberto Maneyro, María Otaran, David Luis Xavier, Susana Garbiero, Julieta Salviu, Patricia Fontenla, Andrea Eckhardt, Carolina Bomparola, Laura Fornasiero. *Medicina Buenos Aires*, **2020**, 80,1-26.  
<https://medicinabuenosaires.com/revistas/vol80-20/s4/indice.pdf>

4. Latino JO, Udry S, Aranda F, Wingeyer SP, Romero DF, Belizna C, **de Larrañaga G**. Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine. *Lupus*. **2020**. <https://doi.org/10.1177/0961203320952850>.
5. Lencina G, Perés S, Aranda F, **de Larrañaga G**. ADMTS-13: diagnóstico de laboratorio. *Hematología*. **2020**, 24 (1). <http://www.revistahematologia.com.ar/index.php/Revista/article/view/256/323>
6. Sebastián Udry; José Omar Latino; Belizna Cristina; Silvia Perés Wingeyer; Diego Fernández Romero; **Gabriela de Larrañaga**. A high-risk laboratory profile of aPL and thrombosis are associated with a large amount of extra-criteria manifestations on primary obstetric antiphospholipid syndrome. *Immunol Res*. **2019**. 67(6), 478-485. <https://doi.org/10.1007/s12026-019-09110-x>
7. Silvia Perés, Federico Aranda, Sebastián Udry, José Latino, **Gabriela de Larrañaga**. Trombofilia hereditaria y pérdidas de embarazo. Estudio de una cohorte de Argentina. *Medicina Clinica (Barcelona)*, **2019**.152:249-254. <https://www.elsevier.es/es-revista-medicina-clinica-2-linkresolver-trombofilia-hereditaria-perdidas-embarazo-estudio-S002577531830071X>
8. **Gabriela de Larrañaga**. Alteraciones de la Hemostasia en la Unidad de Terapia Intensiva. *Hematología* **2018**,22:21-29. [http://www.sah.org.ar/revista/buscar\\_autor.asp](http://www.sah.org.ar/revista/buscar_autor.asp)
9. Latino JO, Udry S, Wingeyer SP, Romero DF, Micone P, **de Larrañaga G**. What is the best time to assess the antiphospholipid antibodies (aPL) profile to better predict the obstetric outcome in antiphospholipid syndrome (APS) patients? *Immunol Res*. **2018**;66(5):577-583. <https://link.springer.com/article/10.1007%2Fs12026-018-9024-5>
10. Federico Aranda, Sebastián Udry, Silvia Perés, Lea Christina Amshoff, Nadja Bogdanova, Peter Wieacker, José Omar Latino, Arseni Markoff and **Gabriela de Larrañaga**. Maternal carriers of the ANXA5 M2 haplotype are exposed to a higher risk for placenta -mediated pregnancy complications. *Journal of Assisted Reproduction and Genetics*. **2018**:35(5):921-928. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984886/>
11. Julián G. Chamorro, Jorge P. Castagnino, Omar Aidar, Rosa M. Musella, Ana Frías, Mabel Visca, Mabel Noguerras, Lucas Costa, Alessandro Perez, Fabio Caradonna and **Gabriela F. de Larrañaga**. Effect of gene-gene and gene-environment interactions associated with anti-tuberculosis drug-induced hepatotoxicity. *Pharmacogenetics and Genomics* **2017**: 10:363-371. <https://insights.ovid.com/crossref?an=01213011-201710000-00003>

12. JO Latino, S Udry, FM Aranda, SDA Perés Wingeyer, DS Fernández Romero and **GF de Larrañaga**. Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile. *Lupus*, February 7, **2017**; pp. 983–988.  
<https://doi.org/10.1177%2F0961203317692432>
13. Martin ES, Schneeberger EE, Aranda FM, Peres SW, Del Carmen Valerio M, de Los Angeles Correa M, Pra FD, Martinez L, Remondino G, **de Larrañaga G**, Citera G. The -2518 A/G polymorphism in the monocyte chemoattractant protein 1 gene (MCP-1) is associated with an increased risk of rheumatoid arthritis in Argentine patients. *Clin Rheumatol.* **2016**;35:3057-3061.  
<https://link.springer.com/article/10.1007%2Fs10067-016-3380-0>
14. Federico Aranda, Silvia D. Perés Wingeyer, Gabriela Camicia, Emilce, Schneeberger, Emilia Saint Martin, Fernando Dal Pra, María de los Ángeles Correa, Gustavo Citera, Martínez Liliana, Mannucci Pablo, Graciela Remondino and **Gabriela F. de Larrañaga**. Q222R polymorphism in the DNase I gene is not associated with susceptibility to rheumatoid arthritis or to disease course in an Argentine patient cohort. *The Egyptian Rheumatologist* **2016**;38:289-293.  
<https://doi.org/10.1016/j.ejr.2016.02.006>
15. Aranda F, Perés Wingeyer S, **de Larrañaga G**. D-Dimer as a prognostic marker of morbidity and mortality among HIV patients: a call for attention. *Infect Dis (Lond)*. **2016**;48: 860-1. <https://link.springer.com/article/10.1007%2Fs10067-016-3380-0>
16. Julián G. Chamorro, Jorge P. Castagnino, Rosa M. Musella, Mabel Nogueras, Ana Frías, Mabel Visca, Omar Aidar, Lucas Costa, **Gabriela F. de Larrañaga**. tagSNP rs1495741 as an useful molecular marker to predict anti-tuberculosis drugs-induced hepatotoxicity. *Pharmacogenetics and Genomics* **2016**; 26:357-61.  
<https://insights.ovid.com/article/01213011-201607000-00006>
17. Gabriela Camicia, Federico Aranda, Sebastián Andrés Muñoz, Alberto Allievi, Alberto Omar Orden, Silvia Perés Wingeyer, Rosana Trobo, Alicia Eimon, Juan Carlos Barreira, Emilce Schneeberger, Judith Sarano, Julio Hofman, **Gabriela de Larrañaga**. Notable association between severe diseases course and nephritis with Q222R polymorphism in DNase I gene among Lupus patients cohort. An argentine multicenter study. Aceptado para publicacion. *Acta Reumatológica Portuguesa* **2016**; 41:138-144. <https://www.ncbi.nlm.nih.gov/pubmed/27606473>
18. Federico Aranda, Silvia D. Perés Wingeyer, Emilce Schneeberger, María Valerio, Emilia Saint Martin, Fernando Dal Pra, María de los Ángeles Correa, Gustavo Citera, Martínez Liliana, Mannucci Pablo, Graciela Remondino and **Gabriela F. de Larrañaga**. The – 308 G/A polymorphism in the Tumor Necrosis Factor- $\alpha$  gene is not associated with development and progression of rheumatoid arthritis in

- Argentinean patients". *International Journal of Rheumatic Diseases* **2016**; 19:476-81. <https://doi.org/10.1111/1756-185X.12343>
19. Aranda F, Perés Wingeyer S y **de Larrañaga G**. Inmunotrombosis: implicancias de las trampas extracelulares de neutrófilos en el desarrollo y progresión de la enfermedad tromboembólica venosa. Aceptado para su publicación en *Revista Argentina de Hematología* **2015**; 19 (3): 231-245.  
[http://www.sah.org.ar/revista/buscar\\_autor.asp](http://www.sah.org.ar/revista/buscar_autor.asp)
  20. Sebastián Pablo Udry, Federico Aranda, Omar Latino and **Gabriela de Larrañaga**. Factor V Leiden and recurrent pregnancy loss. A new concept behind fetal genetics: reply. *Journal of Thrombosis and Haemostasis* **2014**; 12:1759-60.  
<https://doi.org/10.1111/jth.12696>
  21. Gabriela Camicia, Roberto Pozner, **Gabriela de Larrañaga**. Neutrophil extracellular traps in sepsis. *Shock: Injury, Inflammation, and Sepsis: Laboratory and Clinical Approaches* **2014**; 42: 286-294.  
<https://insights.ovid.com/article/00024382-201410000-00002>
  22. Perés Wingeyer S, Oliva S, Chamorro J, Aranda F, Santoro J, Corti M, **de Larrañaga G**. Trombosis venosa profunda en pacientes infectados por el virus de la inmunodeficiencia humana. rol de la trombofilia hereditaria y adquirida y de los factores de riesgo tradicionales. *Revista Argentina de Hematología* **2014**; 18:117-125. [http://www.sah.org.ar/revista/buscar\\_autor.asp](http://www.sah.org.ar/revista/buscar_autor.asp)
  23. Sebastián Pablo Udry, Federico Aranda, Omar Latino and **Gabriela de Larrañaga**. Factor V Leiden and recurrent pregnancy loss. A new concept behind fetal genetics?. *Journal of Thrombosis and Haemostasis* **2014**; 12:666-9.  
<https://www.ncbi.nlm.nih.gov/pubmed/24977289>
  24. Berman H, Rodríguez-Pintó I, Cervera R, Gregory S, de Meis E, Rodriguez CE, Aikawa NE, de Carvalho JF, Springer J, Niedzwiecki M, Espinosa G; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (**European Forum on Antiphospholipid Antibodies**). Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the "CAPS Registry". *Autoimmun Rev*. 2014; 13:157-62. <https://doi.org/10.1016/j.autrev.2013.10.004>
  25. Sebastián Muñoz, Alberto Allievi, Alberto Orden, Silvia Perés Wingeyer, Roxana Trobo, Analía Alvarez, Alicia Eimon, Juan Carlos Barreira, Emilce Schneeberger, Gustavo Citera, Judith Sarano, Julio Hofman, Julián Chamorro, Federico Arana, **Gabriela de Larrañaga**. "4G/5G Plasminogen Activator Inhibitor-1 and -308 A/G Tumor Necrosis Factor- $\alpha$  promoter gene polymorphisms in Argentineans Lupus Patients. Focus on Lupus Nephritis". *Clin Exp Med* **2014**; 14:83-9.  
<https://link.springer.com/article/10.1007%2Fs10238-012-0221-6>

26. Berman H, Rodríguez-Pintó I, Cervera R, Morel N, Costedoat-Chalumeau N, Erkan D, Shoenfeld Y, Espinosa G; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (**European Forum on Antiphospholipid Antibodies**). Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. *Autoimmun Rev.* **2013**; 12:1085-90. <https://doi.org/10.1016/j.autrev.2013.05.004>
27. Sebastián Udry, Federico Aranda, Omar Latino y **Gabriela de Larrañaga**. Anexinas y pérdida recurrentes de embarazo. *Medicina (Buenos Aires)* **2013**; 73:495-500. <http://www.scielo.org.ar/cgi-bin/wxis.exe/iah/>
28. Julián G. Chamorro, Jorge P. Castagnino, Rosa M. Musella, Mabel Nogueras, Federico M. Aranda, Ana Frías, Mabel Visca, Omar Aidar, Silvia Perés and **Gabriela F. de Larrañaga**. Sex, ethnicity and slow acetylator profile are the major responsables of antituberculosis drug-induced hepatotoxicity. *J Gastroenterol Hepatol* **2013**; 28:323-8. <https://doi.org/10.1111/jgh.12069>
29. G. Camicia y **G de Larrañaga**. Trampas extracelulares de neutrófilos (NETs): un mecanismo de defensa con doble cara. *Medicina Clínica (Barcelona)* **2013**; 140:70-5. <https://www.elsevier.es/es-revista-medicina-clinica-2-linkresolver-trampas-extracelulares-neutrofilos-un-mecanismo-S0025775312004666>
30. Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, Pons-Estel G, Cervera R; Catastrophic Antiphospholipid Syndrome (CAPS) **Registry Project Group**. Relapsing catastrophic antiphospholipid síndrome potential role of microangiopathic hemolytic anemia in disease relapses. *Semin Arthritis Rheum* **2013**; 42:417-23. <https://doi.org/10.1016/j.semarthrit.2012.05.005>
31. J. G. Chamorro, J. P. Castagnino, R. M. Musela, A. Frías, F. M. Aranda and **G. F. de Larrañaga**. "Distribution of allelic and genotypic frequencies of N-Acetyltransferase-2 variants in an Argentine population". *The Journal of Infection in Developing Countries* **2012**; 6:671-4. <https://jids.org/index.php/journal/article/view/23000867>
32. Silvia Perés Wingeyer, Eleonora Cunto, Cristina Nogueras, Jorge San Juan, Gómez Norberto, **Gabriela de Larrañaga**. Predictive variables in sepsis at time 0: intensive care unit scores, plasmatic measurements and polymorphisms. An Argentinian cohort study. *The Journal of Infection in Developing Countries* **2012**; 6:555-62. <https://jids.org/index.php/journal/article/view/22842942>
33. Federico Aranda, Silvia Perés Wingeyer, Sebastián Andrés Muñoz, Alberto Allievi, Alberto Orden, Rosana Trobo, Analía Álvarez, Alicia Eimon, Juan Carlos Barreira, Emilce Schneeberger, Judith Sarano, Julio Hofman, **Gabriela de Larrañaga**. The -2518 A/G polymorphism in the Monocyte Chemoattractant Protein 1 gene is associated with the risk of development of Systemic Lupus Erythematosus in

- Argentinean patients. A multicentric study. *European Cytokine Network* **2012**, 23:7-11. [https://www.jle.com/fr/revues/ecn/e-docs/the\\_2518\\_a\\_g\\_polymorphism\\_in\\_the\\_monocyte\\_chemoattractant\\_protein\\_1\\_gene\\_is\\_associated\\_with\\_the\\_risk\\_of\\_developing\\_systemic\\_lupus\\_erythematosus\\_in\\_argentinean\\_patients\\_a\\_multicenter\\_study\\_292273/article.phtml](https://www.jle.com/fr/revues/ecn/e-docs/the_2518_a_g_polymorphism_in_the_monocyte_chemoattractant_protein_1_gene_is_associated_with_the_risk_of_developing_systemic_lupus_erythematosus_in_argentinean_patients_a_multicenter_study_292273/article.phtml)
34. Silvia D. Perés Wingeyer, Mabel N. Graffigna, Susana H. Belli, Jorge Benetucci and **Gabriela F. de Larrañaga**. Role of -675 4G/5G in the Plasminogen Activator Inhibitor-1 gene and -308G/A Tumor Necrosis Factor- $\alpha$  gene polymorphisms in obese Argentinean patients”. *Genetic Testing and Molecular Biomarkers*, **2012**; 16:372-5. <https://doi.org/10.1089/gtmb.2011.0253>
  35. R. Forastiero, M. Martinuzzo, **G. de Larrañaga**, M. Vega-Ostertag, S. Pierangeli. Anti- $\beta$ 2glycoprotein I Antibodies from Leprosy Patients Do Not Show Thrombogenic Effects in an In Vivo Animal Model. *Journal of Thrombosis and Haemostasis* **2011**; 9:859-890. <https://doi.org/10.1111/j.1538-7836.2011.04197.x>
  36. Cervera R; **CAPS Registry Project Group**. Catastrophic antiphospholipid síndrome (CAPS): update from “CAPS Registry. *Lupus* **2010**; 19:412-8. <https://doi.org/10.1177%2F0961203309361353>
  37. Silvia Perés Wingeyer, Susana Belli, Mabel Graffigna, Oscar Levalle, **Gabriela de Larrañaga**. Relationship between 4G/5G polymorphism in the Plasminogen Activator Inhibitor-1 gene and obesity in Argentinian Hispanic adults. *Blood Coagulation & Fibrinolysis* **2010**; 21:196-8. <https://insights.ovid.com/crossref?an=00001721-201003000-00018>
  38. Silvia Perés Wingeyer, Eleonora Cunto, Laura Fontana, Cristina Nogueras, Jorge San Juan, **Gabriela de Larrañaga**. Role of 4G/5G promoter polymorphism of Plasminogen Activator Inhibitor-1 (PAI-1) gene in outcome of sepsis. *Thrombosis Research* **2010**; 125:367-369. <https://doi.org/10.1016/j.thromres.2009.04.006>
  39. Cervera R, Bucciarelli S, Plasín MA, Gómez-Puerta JA, Plaza J, Pons-Estel G, Shoenfeld Y, Ingelmo M, Espinosa G; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (**European Forum On Antiphospholipid Antibodies**). Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". *J Autoimmun.* 2009; 32:240-5. <https://doi.org/10.1016/j.jaut.2009.02.008>
  40. **Gabriela de Larrañaga**, Edgardo Bottaro, Marta Martinuzzo, Raúl Figueroa, María Luisa Iglesias Varela, Silvia Perés Wingeyer, Ricardo Forastiero, Yolanda Adamczuk, Marcelo Corti, Liliana Puga, Jorge Benetucci. Thrombophilia in HIV infected patients with Osteonecrosis: is there a real connection? The first case-control study. *Clinical and Applied Thrombosis and Hemostasis* **2009**; 15:340-7. <https://doi.org/10.1177%2F1076029607310217>

41. Mabel Graffigna, Susana Belli, **Gabriela de Larrañaga**, Hugo Fainboim, Claudio Estepo, Silvia Perés Wingeyer, Natalia García, Oscar Levalle. La proteína transportadora del factor de crecimiento insulínico tipo 1: ¿un nuevo marcador para la enfermedad hepática grasa no alcohólica?. *acta gastroenterológica latinoamericana* **2009**, 39:30-7.  
<https://www.ncbi.nlm.nih.gov/pubmed/19408737>
42. **Gabriela de Larrañaga**, Silvia Perés Wingeyer, Mabel Graffigna, Susana Belli, Karla Bendezú, Silvia Álvarez, Oscar Levalle, and Hugo Fainboim. "Plasma PAI-1 Levels and Nonalcoholic Fatty Liver in Individuals with Features of Metabolic Syndrome". *Clinical and Applied Thrombosis and Hemostasis* **2008**; 14:319-24.
43. Silvia D. Perés Wingeyer, **Gabriela F. de Larrañaga**, Susana H. Belli, Mabel N. Graffigna and Hugo Fainboim. "The range of "normal" values of liver enzymes in the era of metabolic syndrome: the need of a re-definition". *European Journal of Gastroenterology & Hepatology* **2008**; 20:589-91.
44. **Gabriela de Larrañaga**, Luis Trombetta, Silvia Perés Wingeyer, Remondino Graciela. "False positive reactions in confirmatory tests for syphilis in presence of antiphospholipid antibodies: misdiagnosis with prognostic and social consequences. *Dermatology Online Journal* **2006**; 12:12.
45. **Gabriela F. de Larrañaga**, Silvia D.A. Perés, Hugo Fainboim, Liliana M. Puga, Beatriz S. Alonso, Jorge A. Benetucci "Hepatitis C virus and its relation with insulin resistance, endothelial perturbation and platelet activation in HIV-HCV coinfecting patients under highly active antiretroviral treatment". *Eur J Clin Microbiol Infect Dis* **2006**; 25:98-103.
46. **de Larrañaga G**, Remondino G, Forastiero R, Cunto E, Narvaitz M, Olenchuk A, Zala N, San Juan J. "Catastrophic antiphospholipid syndrome and Kikuchi Fujimoto disease: the first case reported". *Lupus* **2005**; 14:967-9.
47. Forastiero RR, Martinuzzo ME, **de Larrañaga GF**. "Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies". *Lupus* **2005**; 14:129-36.
48. **Gabriela F. de Larrañaga**, Graciela Remondino, Beatriz S. Alonso, Liliana Voto. "Soluble thrombomodulin levels among women with history of recurrent pregnancy loss, with or without antiphospholipid antibodies". *Blood Coagulation & Fibrinolysis*, **2005**; 16:31-5.
49. **de Larrañaga G**, Peres S, Benetucci J. "Relationship between enzymes and insulin resistance syndrome markers in HIV with lipodystrophy". *Hepatology* **2004**; 40:1475-6.



50. **G. de Larrañaga**, S. Perés, L Puga, B Alonso, J Benetucci. "Association between the acquired free protein S deficiency in HIV-infected patients with the lipid profile levels". *Journal of Thrombosis and Haemostasis* **2004**; 2:1195-7.
51. **Gabriela de Larrañaga**, Ana Galich, Liliana Puga, Beatriz Alonso, Jorge Benetucci. "Insulin resistance status is an important determinant of PAI-1 levels in HIV infected patients, independently of the lipid profile". *Journal of Thrombosis and Haemostasis* **2004**; 2:532-4.
52. R. R. Forastiero, M. E. Martinuzzo, **G. de Larrañaga**, G. J. Broze Jr. "Autoantibodies anti Tissue Factor Pathway Inhibitor are uncommonly detected in Patients with Infection-related Antiphospholipid Antibodies". *Journal of Thrombosis and Haemostasis* **2003**; 1:2250-1.
53. **Gabriela F. de Larrañaga**, Andrea R. Bocassi, Liliana M. Puga, Beatriz S. Alonso, Jorge A. Benetucci, "Endothelial markers and HIV infection in the Era of Highly Active Antiretroviral Treatment". *Thrombosis Research* **2003**; 110:93-8.
54. **Gabriela F. de Larrañaga**, Alejandro Petroni, Gabriel Deluchi, Beatriz S. Alonso, Jorge A. Benetucci, "Viral load and diseases progression as responsible for endothelial activation and/or injury in HIV-1 infected patients" *Blood Coag & Fibrinolysis* **2003**; 14:15-8.
55. **de Larrañaga Gabriela**, Alonso Beatriz, Puga Liliana, Benetucci Jorge. "Homocisteína plasmática en infectados con el virus de la inmunodeficiencia humana". *Medicina* **2003**; 63:393-8.
56. Marta E. Martinuzzo; **Gabriela F. de Larrañaga**; Ricardo R. Forastiero; Yanina Pelegri; María H. Fariña; Beatriz S. Alonso, Lucía C. Kordich; Luis O. Carreras. "Markers of platelet, endothelial cell and blood coagulation activation in leprosy patients with antiphospholipid antibodies" *Clin Exp Rheumatol* **2002**; 20:477-83.
57. **G. de Larrañaga**, M. Martinuzzo, A. Bocassi, M. Migaud Fressart, R. Forastiero, "Heparin-platelet factor 4 induced antibodies in patients with either autoimmune or alloimmune antiphospholipid antibodies". *Thrombosis and Haemostasis* **2002**; 88:371-3.
58. Raul C. Rey, **Gabriela de Larrañaga**, Sandra Lepera, Marcela Cohen, Gustavo Saposnik, Beatriz Alonso, Roberto E. P. Sica, "Activated protein C resistance in patients with arterial ischemic stroke". *Journal of Stroke and Cerebrovascular Diseases* **2001**; 10:128-31.
59. **de Larrañaga GF**, Forastiero RR, Martinuzzo ME, Carreras LO, Tsariktsian G, Sturno MM, Alonso B. "High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity". *Lupus* **2000**; 9:594-600.

60. **de Larrañaga Gabriela F.**, Harris E. Nigel, Pierangeli Silvia S., Alonso Beatriz S., Schroder Teresa, Fainboim Hugo. “Baja prevalencia de anticuerpos antifosfolípidos en enfermedades hepáticas. *Medicina* **2000**; 60:919-22.
61. **Gabriela de Larrañaga**, Ricardo Forastiero, Luis O. Carreras, Beatriz Alonso. “Different types of antiphospholipid antibodies in AIDS. A comparison with syphilis and the antiphospholipid syndrome”. *Thrombosis Research* **1999**; 96:19-25.
62. **Gabriela de Larrañaga**, Ricardo Forastiero, Luis O. Carreras, Norma Zala, Liliana Guzmán, Beatriz Alonso. “Acquired hypoprothrombinemia related to high titers of antiprotein-phospholipid antibodies”. *Thrombosis and Haemostasis* **1999**; 81:317-8.

#### CO-AUTHOR OF CHAPTER IN INTERNATIONAL BOOK

63. "New insights exploring differences between APS and infectious related aPL". Forastiero R, Martinuzzo M, **de Larrañaga G.** Nueva edición del libro "New research on autoantibodies". Capítulo V, **2007**. Autor: Claude T. Petrelli, Editor: Claude T. Petrelli, edición ilustrada, Editorial: Nova Publishers, ISBN: 160456055X, 213 páginas.

#### CO-AUTHOR OF CHAPTER IN NATIONAL BOOK

64. Guía de laboratorio para el estudio de los anticuerpos antifosfolípidos (aPL) en fase sólida. Guía **CAHT 2020**. Coordinador: Ricardo Forastiero. Comité editor: **Gabriela de Larrañaga** / Lourdes Herrera. ISBN: 978-987-21580-6-4.
65. Guía de laboratorio para el estudio de los anticuerpos antifosfolípidos (aPL) en fase sólida. Guía **CAHT 2020**. Coordinador: Ricardo Forastiero. Comité editor: Gabriela de Larrañaga / Lourdes Herrera. **Capítulo 2**: Tipos de anticuerpos antifosfolípidos y epitopes antigénicos. ISBN: 978-987-21580-6-4.
66. “Fundamentos para el manejo práctico en el laboratorio de hemostasia”. Libro editado por el Grupo CATH. Redacción junto con otros colegas de un capítulo del libro. **2013**, Buenos Aires, Argentina.
67. “Fundamentos para el manejo práctico en el laboratorio de hemostasia”. Libro editado por el Grupo CATH. Redacción junto con otros colegas de un capítulo del libro. Presentado el 28 de Marzo de **2003**, Buenos Aires, Argentina.

#### PUBLICATION IN A NATIONAL SCIENTIFIC JOURNAL WITHOUT PEER-REVIEWER

68. Chamorro Julián, Castagnino Jorge, Musella Rosa María, Aidar Omar, Frias Ana, Nogueras Mabel, Costa Lucas y **de Larrañaga Gabriela**. Novedoso marcador molecular para predecir el desarrollo de hepatotoxicidad inducida por fármacos antituberculosis. Revista Argentina de Infectología D. Francisco J. Muñiz **2015**.
69. Camicia G, de Larrañaga G. Trampas extracelulares de neutrófilos: rol de este novel mecanismo de defensa en las infecciones parasitarias. Revista Argentina de Zoonosis y Enfermedades Infecciosas Emergentes **2012**; 7:25-29.
70. Camicia G, **de Larrañaga G**. Morir por una causa: nuevo mecanismo de defensa de neutrófilos. Revista Argentina de Infectología D. Francisco J. Muñiz **2012**; 15:57-62
71. S. Perés Wingeyer, E. Cunto, A. Lucero, J. Chamorro, C. Nogueras, J. San Juan, N. Gómez, B. Alonso, **G. de Larrañaga**. Variables predictivas en sepsis a tiempo 0: scores utilizados en la unidad de cuidados intensivos, concentraciones plasmáticas y polimorfismos. Estudio de una cohorte argentina. ”. Muñiz Hoy **2011**; 14:21-24.
72. Trombetta L, Perés Wingeyer S, **de Larrañaga G**, Remondino G. “¿Sífilis o enfermedad autoinmune?”. Muñiz Hoy **2009**;12:83-86.
73. **de Larrañaga Gabriela**, Alonso Beatriz, Alejandro de Larrañaga. "Implicancias del efecto 2000 en los equipos / sistemas de salud”. Muñiz Hoy **1999**; 2:89-96.
74. **de Larrañaga Gabriela**, Gómez Norberto, Alonso Beatriz, "Cambios en los perfiles bioquímicos en pacientes HIV". Muñiz Hoy **1999**; 2 (3) 72-74.
75. **de Larrañaga Gabriela**, Arroyo Karina, Alonso Beatriz. "Homocisteína vs. colesterol". Muñiz Hoy **1999**; 2:43-50.
76. de de Larrañaga Nora, **de Larrañaga Gabriela**, Alonso Beatriz, Luna Suárez Stella, “Sangrados peri operatorios: a propósito de un caso”. Revista de la Asociación Odontológica Argentina **1998**; 86:214-215.
77. R. C. Rey y **G. F. de Larrañaga**. “Stroke isquémico y anticuerpos antifosfolípidos”. Revisión. Revista de Neurología Argentina **1996**; 21: 54-66.